Theriva Biologics unveils positive preclinical data for VCN-12, showing superiority over VCN-01

Theriva Biologics, Inc.

VCN-12 showed up to 13.7x greater cytotoxicity than VCN-01 across multiple cancer cell lines in vitro.
In HP-1 pancreatic tumor hamster model, VCN-12 significantly reduced growth in both injected and non-injected tumors.
Complete tumor regression in 2/9 hamsters; those animals rejected tumor re-challenge 43 days later.
VCN-12 incorporates bee hyaluronidase (higher activity) and parasporin-2 to enhance immunogenic cell death.
Toxicity profile in mice similar to VCN-01; further preclinical studies planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.